trending Market Intelligence /marketintelligence/en/news-insights/trending/ww3ezz6kd4vamxmuxvg04a2 content esgSubNav
In This List

AbbVie's blockbuster drug Humira secures another approval in Japan

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


AbbVie's blockbuster drug Humira secures another approval in Japan

AbbVie Inc. and Eisai Co. Ltd. said Humira was approved in Japan as a treatment for an autoimmune disease known as pustular psoriasis.

Humira, AbbVie's blockbuster drug, is already approved for nine other indications in the country. Tokyo-based Eisai has the rights to market the drug in Japan.

The approval for a new indication was based on a phase 3 trial in Japanese patients whose conditions did not improve after being treated with conventional medicines, such as etretinate and cyclosporine.

About 70% of the patients showed a reduction in their disease after 16 weeks of treatment in that trial.

Humira treats a range of autoimmune disorders from rheumatoid arthritis to plaque psoriasis and ulcerative colitis.